Premium
The cost of severe refractory epilepsy: comparison of patient response to adjunct vigabatrin
Author(s) -
Souêtre E.,
Taïeb C.,
Lozet H.,
Boilait C.,
Castelain V.,
Bacquet P.
Publication year - 1997
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.1997.tb00366.x
Subject(s) - vigabatrin , medicine , refractory (planetary science) , adjunct , partial epilepsy , epilepsy , indirect costs , anesthesia , pediatrics , anticonvulsant , psychiatry , linguistics , physics , accounting , astrobiology , business , philosophy
Data from 112 patients with severe, refractory, partial epilepsy, who were treated with adjunct vigabatrin, were used to compare the cost‐of‐care for patients who responded to the therapy and those who did not. For patients who responded to vigabatrin, the direct and indirect costs were lower than the costs for patients who did not respond to treatment. The major impact on direct costs was a 69% and 59% decrease in rate of hospitalization and length of stay in hospital, respectively, for the responder group. This decrease in costs outweighed the additional drug costs associated with continued vigabatrin therapy.